|
(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) Clinical Trials
1 actively recruiting trial across 1 location
Bethesda, Maryland1 trial
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
National Institutes of Health Clinical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.